Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.
The U.S. Food and Drug Administration (FDA) approved Empaveli on May 14. It is available only through a Risk Evaluation and Mitigation Strategy (REMS).
Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
